HOME >> BIOLOGY >> NEWS
Penicillin, amoxicillin: Step aside for strep throat treatment

Doctors today presented more evidence that it's time for long-time antibiotic stalwarts like penicillin and amoxicillin to step aside when it comes to the treatment of strep throat.

The most common medications used to treat the strep germ, the bug that causes millions of sore throats in U.S. children every year, simply aren't doing the job and aren't as effective as newer antibiotics known as cephalosporins. In results presented today at a large infectious disease meeting, the annual Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington, doctors who reviewed the treatment given to 11,426 children showed that even a short course of the newer drugs is more effective than the traditional 10-day dose of the older antibiotics.

Pediatricians at the University of Rochester Medical Center found that 25 percent of children treated for strep throat with penicillin ended up back in the doctor's office within three weeks of treatment. Children treated with amoxicillin returned 18 percent of the time. The numbers were 14 percent for older-generation cephalosporins, and just 7 percent for newer ones like cefpodoxime and cefdinir, which are given for just four or five days.

The new results buttress previous work by physicians Michael Pichichero, M.D., and Janet Casey, M.D., showing that more children who receive the older drugs relapse, prolonging their illness and forcing doctors to turn to even stronger drugs. Yet, said Pichichero, doctors across the land continue to prescribe ineffective medications. Studies have shown that approximately 60 to 80 percent of children treated for strep are prescribed amoxicillin; 10 to 20 percent are prescribed penicillin; and just 10 to 20 percent receive a cephalosporin.

"Most doctors are shocked to learn of the high failure rates of the older medications," said Pichichero, a professor of Microbiology and Immunology.

"The treatment paradigm for treating strep sore throats has bee
'"/>

Contact: Tom Rickey
tom_rickey@urmc.rochester.edu
585-275-7954
University of Rochester Medical Center
17-Dec-2005


Page: 1 2 3

Related biology news :

1. Cloning the smell of the seaside
2. Exercise aside, genes may ultimately dictate seniors mobility
3. Blood test may help signal tumors remission, return in throat cancer patients
4. The greenbeards have blue throats in a breakthrough study of the evolution of altruistic behavior
5. Birdsong sounds sweeter because throats filter out messy overtones
6. New system of wastewater treatment could reduce the size of treatment plants by half
7. UCF research links proteins, stem cells and potential Alzheimers treatment
8. Geisinger scientist seeks cure for Lou Gehrigs disease, creating device to find treatment
9. System to analyze beating heart stem cells could lead to heart attack treatments
10. Gene expression pattern could lead to improved treatment of pediatric septic shock
11. Molecular detectors may refine cancer treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received approval from ... and ProText™, making them the first Wharton’s jelly allografts to be assigned a Q ... company’s solutions are the first Wharton’s jelly allograft product to be recognized as a ...
(Date:7/22/2020)... ... July 21, 2020 , ... ... innovation in technology and compliance, announces a new solution to manage regulated workloads ... every layer of their technology stack complies with FDA and global regulations. USDM's ...
(Date:7/10/2020)... CHICAGO (PRWEB) , ... July 09, 2020 , ... Today ... Umami Advantage, which will share insight on the “fifth taste” phenomenon that is revolutionizing ... snacks. The Umami Advantage will be live on Monday, July 13, 2020 at11:00 AM ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... (PRWEB) , ... July 17, 2020 , ... ... global consulting firm for the life sciences and food industries, is pleased to ... Director of Clinical Research – Business Development. , Charles is an accomplished and ...
(Date:7/10/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company ... Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will join ... Dr. Nissenson serves as an Emeritus Professor of Medicine at the David ...
(Date:7/1/2020)... ... 29, 2020 , ... The Interlocal Purchasing System (TIPS), a ... recently named BioFit Engineered Products an Awarded Vendor. Awarded Vendor status ... cafeteria tables, book trucks and carts at discounted pricing without the delay and ...
(Date:6/28/2020)... HILL, Conn. (PRWEB) , ... June 25, 2020 ... ... company formed to advance photodynamic therapy for treating cancer, today announced the company ... New York (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to ...
Breaking Biology Technology:
Cached News: